Artemisia annua for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Artemisia annua for Health & Longevity

Created on 09/22/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Artemisia annua, a bitter garden herb sold as tea, capsules, and leaf powder, is used for joint pain, allergy, and parasites. Its leaf chemical turns destructive around iron — the property behind its effect, its liver strain, and its danger. Using the plant's own pollen to build allergy tolerance has the strongest human record; joint pain and immune recovery each rest on one small trial. (Full Review)

Protocol

Standardized extract, the best-documented supplement form
150 mg twice daily
The regimen that produced pain and function gains over 12 weeks in the only placebo-controlled joint trial. Higher doses have no supporting outcome data.
Dried whole-leaf powder
Gram-scale daily doses
Milled leaf, the form used in the antiretroviral add-on trial. Artemisinin content varies widely by cultivar, so labelled milligram content matters more than leaf weight.
Best time of day
With the largest fat-containing meal
Usually midday. The compound is lipophilic and poorly water-soluble, and food markedly improves its absorption.
Time to effect
Allergy desensitization
A full pollen season
The sublingual pollen extract needs a complete season; the effect persisted into the following one.
Parasite and fever clearance
24–48 hours
Early clearance is real and reproducible, while sustained cure falls far short of artemisinin-based combinations.
Joint pain and function
12 weeks
Improved over 12 weeks in the placebo-controlled trial and continued improving to 48 weeks in rheumatoid arthritis.

Benefits

Contraindications
  • Pregnancy, particularly the first trimester (gestational weeks 0–13), and anyone actively trying to conceive
  • Breastfeeding
  • Known allergy to Asteraceae plants (mugwort, ragweed, chamomile, chrysanthemum, echinacea)
  • Active or chronic liver disease, or baseline aminotransferases above twice the upper reference limit
  • Documented glucose-6-phosphate dehydrogenase deficiency with any prior haemolytic episode
  • Iron overload states (hereditary haemochromatosis, transfusion dependence, ferritin above 1,000 ng/mL)
  • Resting heart rate below 50 beats per minute, or second- or third-degree heart block
  • Children under five years
  • Cancer chemotherapy (doxorubicin, oxaliplatin, temozolomide) outside oncology supervision
    •
Key Interactions
  • Antiretroviral and immunosuppressant drugs (efavirenz, nevirapine, tacrolimus, cyclosporine)
  • CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, grapefruit juice)
  • Anticoagulants and antiplatelet drugs (warfarin, apixaban, clopidogrel)
  • Over-the-counter analgesics and antacids (acetaminophen, ibuprofen, proton pump inhibitors)
  • Iron and vitamin C supplements
  • Hepatically demanding botanicals (green tea extract, kava, black cohosh, comfrey)
  • Additive antiparasitic and anti-inflammatory supplements (berberine, oregano oil, black walnut, curcumin)
  • Therapeutic phlebotomy, iron chelation, and high-dose intravenous vitamin C
    •

Risk & Side Effects

  • High: Local and systemic allergic reactions; gastrointestinal intolerance
  • Low: Embryo-fetal harm in early pregnancy; drug-induced liver injury; delayed destruction of red blood cells; bradycardia and other cardiac conduction effects
  • Speculative: Brainstem injury with sustained high exposure; immune suppression with continuous long-term use

Monitoring

Marker Target Why
ALT < 25 U/L (men), < 20 U/L (women) Earliest marker of hepatocellular injury
AST < 26 U/L Confirms and stages a liver signal seen on ALT
ALP and total bilirubin ALP 40–90 U/L; bilirubin 0.3–1.0 mg/dL Detects the cholestatic and bile-duct pattern reported with this herb
Complete blood count with reticulocytes Haemoglobin 13.5–15.0 g/dL (men), 12.5–14.0 g/dL (women); reticulocytes 0.5–2.0% Catches delayed red-cell destruction and marrow response
Ferritin 50–150 ng/mL Sets how much iron is available to drive the compound's mechanism
Transferrin saturation 25–35% Distinguishes true iron loading from inflammatory ferritin elevation
hs-CRP < 1.0 mg/L Tracks the inflammatory outcome the joint trials measured
G6PD activity Normal enzyme activity by laboratory reference; no optimal target exists Identifies the enzyme deficiency that worsens any haemolytic episode
eGFR and creatinine eGFR > 90 mL/min/1.73 m²; creatinine 0.7–1.1 mg/dL Confirms the clearance route for metabolites is intact

Cadence: Baseline before the first dose, then at 4 weeks, at 12 weeks, then every 3–6 months while use continues, with an additional check within two weeks of any dose increase, any new medication cleared by the liver, or any onset of dark urine, itching, or right-sided abdominal discomfort.

Qualitative Assessment

  • Joint pain, morning stiffness, and physical function, scored weekly on a simple 0–10 scale
  • Nasal congestion, sneezing, and eye irritation across the relevant pollen season
  • Digestive comfort — nausea, cramping, and stool consistency in the hours after dosing
  • Energy through the afternoon, and any unexplained fatigue that persists across days
  • Skin and eye colour, itching, and urine darkness, checked whenever fatigue appears
  • Hearing, tinnitus, and steadiness on the feet, the animal-derived warning signs
  • Resting heart rate on waking, tracked for a downward drift below the personal baseline
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.